Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: A case report

Innovations in Clinical Neuroscience

Volumn 9, Issue 3, 2012, Pages 13-16

  Safer, Debra L ^a   Arnow, Katherine D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anorexia nervosa; Depression; Duloxetine; Obsessive compulsive disorder; Suprathreshold

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; DULOXETINE; RISPERIDONE;

ABSENCE OF SIDE EFFECTS; ADULT; ANOREXIA NERVOSA; ARTICLE; BINGE EATING DISORDER; CASE REPORT; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FAMILY HISTORY; FATIGUE; FEMALE; GROUP THERAPY; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PSYCHOLOGIC ASSESSMENT; SEDATION; SIDE EFFECT; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84860904580     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? a meta-analysis of studies of newer agents. Biol Psychiatry. 2007; 62:1217-1227.
2. Lieberman DZ, Massey SH. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2009;4:67-82.
3. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007;27:672-676.
4. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63(4):424-434. Epub ahead of print. 2007 Sep 24.
5. Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther. 2010;35:177-188.
6. Stahl SM, Grady MM, Moret, C, Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747.
7. Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry. 2006;67(4):600-610.
8. Dell'Osso B, Mundo E, Marazziti D, Altamura AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008;22(2):210-213.
9. Christensen RC, Averbuch RN. The use of duloxetine in chronic bulimia nervosa: case report. Psychiatry (Edgemont). 2009;6(8):27-28.
10. Bernardi S, Pallanti, S. Successful duloxetine treatment of a binge eating disorder: a case report. J Psychopharmacol. 2010;24(8):1269-1272.
11. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive compulsive disorder. Washington, DC: American Psychiatric Press, Inc.; 2007.
12. Yeh YW, Chen CH, Kuo SC, et al. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol. 2009;32(3):174-176.
13. Brecht S, Desaiah D, Marechal ES, et al. Efficacy and safety of duloxetine 60mg and 120mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry. 2010; Sep 21. Epub ahead of print.
14. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007;21(7):581-609.
15. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007; 49:146-153.
16. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281-294.